Replies to post #75400 on NanoViricides Inc. (NNVC)

[changes_iv]

Thank you BigKahuna. The article linked to your post is very encouraging for the remainder of 2013 and should help build anticipation for 2014, the year of the "shifting-paradigm of antiviral drugs", NanoViricides, Inc.

Nanoviricides: A New Hero in Antiviral Science

Revolutionizing the archaic vaccine system.
http://www.bu.edu/synapse/2011/11/27/nanoviricides/

"As a nation that has always prided itself on being at the forefront of progress, the reality is that the United States has reached a point of stagnation regarding the development of the current vaccine system. The U.S. is losing ground and needs to act quickly in the face of growing viral diseases and unfortunately, the present vaccine system doesn’t allow for this. With more research and development, the United States can support and look forward to the development of better, safer vaccines that allow us to battle disease on its own terms. Nanoviricides present a compelling war plan.

We would like to thank the CEO of NanoViricides, Eugene Seymour, for kindly agreeing to provide input and insight on this article."

Excerpt from 2009 Jain Report: Structure and function of nanoviricides

source: http://allallan.blogspot.com/2009/04/nnvc-why-so-special.html

Advantages of NanoViricides

§ The biological efficacy of NanoViricides drugs may be several orders of magnitude better than that of of usual chemical drugs. This in itself may limit the potential for mutant generation.

§ Low cost of drug development, manufacture, distribution.

more: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91021791

[JG36]

Nothing there is relevant to NNVC. All the "enriched studies" described are for trials on people who have the disease. NNVC's Phase I trials will be on healthy human beings not deliberately exposed to the virus. You have failed to explain how any amount of excellent statistics could enable NNVC to establish strong evidence of efficacy in such trials.

The fact: NNVC will do Phase I trials of Flucide, then small scale Phase II trials, and at that point may or may not have sufficiently strong evidence of efficacy to get FDA approval.